Pharmacy Times
JANUARY 1, 2025
Lp(a) is a critical risk factor for atherosclerotic cardiovascular disease, but current lipid-lowering therapies are largely ineffective at lowering Lp(a) levels.
Pharmaceutical Commerce
JANUARY 1, 2025
This bucket of Pharma Commerce coverage is highly powered by digital solutions.
Pharmacy Times
JANUARY 1, 2025
Administering first-dose antibiotics to septic shock patients via IV push rather than continuous infusion could improve the speed of antibiotic delivery and reduce logistical challenges.
PharmaTech
JANUARY 1, 2025
In a discussion on bispecific antibody development, Atul Mohindra, head of Biologics R&D at Lonza, points out the challenges and successes of these molecules as well as the fields future direction from a CDMO perspective.
Advertiser: ZoomInfo
Sales and marketing leaders have reached a tipping point when it comes to using intent data — and they’re not looking back. More than half of all B2B marketers are already using intent data to increase sales, and Gartner predicts this figure will grow to 70 percent. The reason is clear: intent can provide you with massive amounts of data that reveal sales opportunities earlier than ever before.
PharmExec
JANUARY 1, 2025
In this Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), speaks about exciting developments in fertility treatment that he anticipates in the next few years.
Pharmacy Times
JANUARY 1, 2025
Some outsourcers and pharmacies have capitalized on the shortages, producing compounded versions.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmacy Times
JANUARY 1, 2025
Female adolescents were at an increased risk of experiencing depression and anxiety symptoms compared with males.
Pharmacy Times
JANUARY 1, 2025
Panelists discuss how elafibranor demonstrated significant efficacy in the ELATIVE trial, which strengthens confidence in its role as a long-term treatment option for patients with primary biliary cholangitis (PBC) who inadequately respond to ursodeoxycholic acid.
Pharmacy Times
JANUARY 1, 2025
Panelists discuss how seladelpar showed remarkable efficacy in the RESPONSE trial, demonstrating significant improvements in alkaline phosphatase levels and other biochemical markers compared with placebo.
Expert insights. Personalized for you.
55 
Let's personalize your content